|Asset||Modality / Target||Regimen||Indication||Discovery||Pre-Clinical||FIH||POC||Pivotal|
|IN10018 Small molecular FAK inhibitor||+ PLD||PROC (double-blind, placebo controlled, randomized study)||
|+ MEKi ± IO||IO-failed NRAS melanoma Uveal melanoma||
|+ PLD ± IO||PROC, TNBC, HNSCC||
|+ chemotherapy + IO||IO-failed NSCLC (randomized study)||
|+ chemotherapy + IO bispecific||Pancreatic cancer||
|+ KRASG12C inhibitor||KRASG12CCRC and NSCLC||
|+3rd EGFR inhibitor||EGFR mutant NSCLC||
|OMTX705||ADC Targeting FAP||Mono / Combo||Solid Tumor||
|INES103||Antibody Target undisclosed||Combo||Solid Tumor||
|IN30718||ADC Target undisclosed||Mono||Solid Tumor||
|IN30728||ADC Target undisclosed||Mono||Solid Tumor||
|IN20019||Small molecular Target undisclosed||Mono||Solid Tumor||
IN10018 is a highly potent and selective inhibitor of the focal adhesion kinase (FAK). Anti-tumor activities of IN10018 have been demonstrated in multiple animal models for human cancers. More than 250 patients have been dosed and IN10018 has showed its safety and promising efficacy signal in platinum ovarian cancer and NRAS melanoma.
IN30705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment.
INES103 is an injectable recombinant humanized VHH (single variable domain of heavy chain, VHH)-Fc fusion protein against tumor associate macrophage（TAM）related target, to be administered for treatment of advanced or metastatic solid tumor and hematological malignancies. INES103 is designed to improve tissue penetration against solid tumors.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
Tel: +86 25-58251030
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing